Nephrotoxicity after PRRT - Still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y- DOTATATE and 90Y/177Lu-DOTATATE

Endokrynologia Polska

Volumn 64, Issue 1, 2013, Pages 13-20

  Kunikowska, Jolanta ^a   Królicki, Leszek ^a   Sowa Staszczak, Anna ^b   Pawlak, Dariusz ^c   Hubalewska Dydejczyk, Alicja ^b   Mikołajczak, Renata ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

Author keywords

90Y DOTATATE; Nephrotoxicity; Neuroendocrine tumours; Peptide receptor radionuclide therapy; Somatostatin receptors; Tandem 90Y 177Lu DOTATATE

Indexed keywords

AMINO ACID; CREATININE; DOTATATE Y 90; DOTATATE Y 90 LU 177; ONDANSETRON; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; RENAL PROTECTION; VOMITING;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RENAL INSUFFICIENCY; YTTRIUM RADIOISOTOPES;

EID: 84876195901     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Christensen EI, Nielsen S. Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol. 1991; 11: 414-439.
2. de Jong M, Rolleman EJ, Bernard BF et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996; 37: 1388-1392.
3. Reubi JC, Horisberger U, Studer UE et al. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. JCEM 1993; 77: 1323-1328.
4. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26: 1439-1447.
5. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with Y-90-DOTATOC. Eur J Nucl Med. 2001; 28: 1552-1554.
6. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21: 109-122.
7. Cremonesi M, Ferrari M, Zoboli S et al. Biokinetics and dosimetry in patients administered with 111InDOTA-Tyr3-octreotide: implications for internal radiotherapy with Y-90-DOTATOC. Eur J Nucl Med 1999; 26: 877-886.
8. Rolleman EJ, Valkema R, de Jong M et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003; 30: 9-15
9. Melis M, Bajster M, de Visser M et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging. 2009; 36: 1968-1976.
10. Rolleman EJ, Melis M, Valkema R et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 1018-1031
11. Davies Dean F, Shock Nathan W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950; 29: 496-507.
12. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Intern Med.1999; 130: 461-470.
13. Klahr S, Levey AS, Beck GJ et al. Modification Of Diet In Renal Disease Study Group: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease: The Modification of Diet in Renal Disease Study. N Eng J Med 1994; 330: 377-884.
14. Murussi M, Gross JL, Silveiro SP. Glomerular filtration rate changes in normoalbuminuric and microalbuminuric Type 2 diabetic patients and normal individuals A 10-year follow-up. J Diabetes Complications. 2006; 20: 210-215.
15. De Cosmo S, Argiolas A, Miscio G et al. Brief Genetics Report A PC-1 Amino Acid Variant (K121Q) Is Associated With Faster Progression of Renal Disease in Patients With Type 1 Diabetes and Albuminuria. Diabetes 2000; 49: 521-524
16. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr 1985; 106: 659-663.
17. Poggio ED, Nef PC, Wang X et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005; 46: 242
18. Rolleman EJ, Valkema R, de Jong M et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30: 9-15.
19. Jamar F, Barone R, Mathieu I et al. Y-86-DOTA0-D-Phe1-Tyr3-octreotide (SMT487): a phase 1 clinical study-pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid coinfusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-518.
20. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabeled somatostatin analog (Lu-177-DOTA0, Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
21. Cohen EP, Moulder JE, Robbins MEC. Radiation nephropathy caused by yttrium 90. Lancet. 2001; 358: 1102-1103.
22. Schumacher T, Waldherr C, Mueller-Brand J et al. Kidney failure after treatment with Y-90-DOTATOC (letter). Eur J Nucl Med 2002; 29: 435.
23. Bodei L, Chinol M, Cremonesi M et al. Facts and myths about radiopeptide therapy: scylla, charibdis and sibyl. Eur J Nucl Med 2002; 29: 1099-1100.
24. Otte A, Cybulla M, Weiner SM. Y-90-DOTATOC and nephrotoxicity. Eur J Nucl Med 2002; 29: 1543.
25. Lambert B, Cybulla M, Weiner SM et al. Renal toxicity after radionuclide therapy. Radiat Res 2004; 161: 607-611.
26. Moll S, Nickeleit V, Mueller-Brand J et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001; 37: 847-851.
27. Waldherr C, Pless M, Maecke HR et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq Y-90-DOTATOC. J Nucl Med. 2002; 43: 610-616.
28. Chinol M, Bodei L, Cremonesi M et al. Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32: 141-147.
29. Bodei L, Cremonesi M, Ferrari M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with Y-90-DOTATOC and Lu-177-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856
30. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue 90Y-DOTA-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-23.
31. Bodei L, Cremonesi M, Grana CM et al. Peptide receptor radionuclide therapy with 137Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011; 38: 2125-2135.
32. Valkema R, Pauwels S, Kvols L et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with Y-90-DOTA0,Tyr3- Octreotide and Lu-177-DOTA0, Tyr3-Octreotate J Nucl Med 2005; 46 (Suppl.): 83S-91S.
33. Barone R, Borson-Chazot F, Valkema R et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005; 46 (Suppl. 1): 99S-106S.